Abstract:Considering the general view that unconventional immune effectors play a major role in antitumor immunity, we recently postulated that the distinct new innate CD8 T-cell pool (co-expressing the transcription factor Eomesodermin and innate markers such as KIR/NKG2A) may counteract tumor cells, and thereby be potential target for cancer therapy. Here, to test this assumption, we used successfully targeted anti-leukemic therapy discontinuation (TFR) in chronic myeloid leukemia (CML). Numerical and functional status of innate CD8 T-cells, iNKT cells and γδ T-cells, in comparison with NK cells, was compared longitudinally between non-relapsed patients (i.e., with > 12 months TFR) and relapsed patients (i.e., who experienced molecular recurrence during the first 12 months after TKI cessation) in a prospective pilot cohort (n=32), starting from treatment discontinuation (D0). Perforin, a key cytotoxic immune player, was expressed in a significantly higher proportion of both innate CD8 T-cell and NK-cell subsets in non-relapsed patients, compared with relapsed patients at D0. In parallel, we assessed the expression of PD-1, an exhaustion marker used as target in cancer therapy. For all T-cell subsets, surface-expression level of PD-1 decreased in non-relapsed patients compared with relapsed patients at D0. This was particularly the case when considering iNKT cells for which surface-expression level of PD-1 even decreased relative to healthy control subjects. Lastly, we found a negative correlation between the proportion of innate CD8 T-cells expressing PD-1 and those expressing perforin in non-relapsed patients at D0. The fact that this was not the case in conventional CD8 T-cells is compatible with a reprogrammed effector profile preferentially targeting innate CD8 T-cells in non-relapsed patients. All in all, our results highlight NK cells and innate CD8 T-cells harboring cytotoxic content, as well as global downregulation of PD-1-expression on effector T-cells, as potential predictive functional signatures for successful TFR in CML. Considering innate CD8 T-cells, further investigations are needed to determine whether their possible contributory role in cancer surveillance in CML could be extended to other cancers, and also whether their targeting by immune cheek-point inhibitors could enhance their anti-tumoral functions.

Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses

CCL3 augment antitumor immune priming in the tumor draining lymph node

CCL2/CCR2-dependent Recruitment of Functional Antigen-Presenting Cells into Tumors Upon Chemotherapy.

IL-3-driven T cell-basophil crosstalk enhances anti-tumor immunity

FLT3L-dependent dendritic cells control tumor immunity by modulating Treg and NK cell homeostasis

Innate Lymphoid Cells Type 3 in Cancer

Type 1 Innate Lymphoid Cells Limit the Antitumoral Immune Response

CD20+CD22+ADAM28+ B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response

The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy

C3aR Signaling Inhibits NK-cell Infiltration into the Tumor Microenvironment in Mouse Models

Induction of antitumor immunity by CCR2 transduced CD8+TILs in mouse lung carcinoma

Interferon-γ driven differentiation of monocytes into PD-L1 and MHC II macrophages and the frequency of Tim-3 tumor-reactive CD8 T cells within the tumor microenvironment predict a positive response to anti-PD-1-based therapy in tumor-bearing mice

Inducible CCR2+ nonclassical monocytes mediate the regression of cancer metastasis

Cancer immunity by tissue‐resident type 1 innate lymphoid cells and killer innate‐like T cells

A novel type-2 innate lymphoid cell-based immunotherapy for cancer

IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer

Conversion of CCL18-recruited Naïve CD4+ T Cells to Tumor-Infiltrating Regulatory T Cells in Breast Cancer and Suppression of Antitumor Immunity.

Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy

CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells.